Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Assignees
MemberSNIPR BiomeSNIPR BiomeSNIPR Biome develops precision medicines for infections and diseases linked to antimicrobial resistance and microbiome dysbiosis, using CRISPR-based gene editing to selectively target pathogenic bacteria while sparing the rest of the microbial community. The company applies programmable CRISPR platforms, delivered by engineered phages or probiotics, to address difficult-to-treat infections and modulate the human microbiome. Its programs span discovery through Phase 2 clinical trials, with a significant patent portfolio supporting these innovations.
SNIPR Biome develops precision medicines for infections and diseases linked to antimicrobial resistance and microbiome dysbiosis, using CRISPR-based gene editing to selectively target pathogenic bacteria while sparing the rest of the microbial community. The company applies programmable CRISPR platforms, delivered by engineered phages or probiotics, to address difficult-to-treat infections and modulate the human microbiome. Its programs span discovery through Phase 2 clinical trials, with a significant patent portfolio supporting these innovations.
Abstract
The invention relates to the production of transduction particles, such as phage, as well as compositions comprising the particles and use of these. The particles are particularly useful for delivering toxic payloads into target bacteria for antibacterial action. The invention is also useful for the production of wild-type (“native”) phage and phage cocktails comprising different types of phage. Embodiments enable production of compositions of such particles for use in medical, environmental or food production settings.
Core Innovation
The invention relates to producing transduction particles that recognize a receptor on bacterial target cells for transduction of the cells. The particles are produced in bacterial producer cells that do not express the receptor on their surface, and this production configuration enhances the production yield compared to producing the transduction particles in bacterial producer cells that express the receptor on their surface.
The described transduction-particle embodiments include phage-based transduction particles and non-self-replicative transduction particle systems. In these embodiments, the documents describe the use of phage capsids and packaging signals, and the inclusion of a nucleic acid sequence of interest encoding antibacterial payloads, including CRISPR/Cas systems with guide RNA and a Cas nuclease.
The disclosure also describes addressing receptor features on bacterial cell surfaces, with particular emphasis on receptors associated with cell-surface structures such as LPS. An experimental Example is described in which producer-cell receptor binding is reduced by knocking out an LPS core biosynthesis gene, resulting in a substantially increased transduction particle yield compared to receptor-expressing producer cells.
Claims Coverage
The partial content identifies one independent claim directed to a method of producing transduction particles with enhanced production yield by preventing receptor surface expression in bacterial producer cells. One inventive feature is extracted from that independent claim.
Producer cells do not express the receptor on their surface to enhance yield
A method of producing transduction particles capable of recognizing a receptor on bacterial target cells for transduction of the cells, wherein the particles are produced in bacterial producer cells that do not express the receptor on their surface, and wherein the production yield is enhanced compared to production in bacterial producer cells that express the receptor on their surface.
Across the provided claim material, the core claim coverage focuses on producing receptor-recognizing transduction particles in producer cells that lack surface expression of the receptor to increase production yield. Dependent refinements are noted in the partial content, but the main inventive feature extracted here is the receptor non-expression in producer cells paired with enhanced yield.
Stated Advantages
Enhanced production yield of transduction particles compared to producing in bacterial producer cells that express the receptor on their surface.
Documented Applications
Treating, preventing, or killing bacterial-mediated disease using antibacterial payloads delivered by transduction particles.
Use of isolated transduction-particle compositions in medical, environmental, and food contexts.
Interested in licensing this patent?